Results 121 to 130 of about 23,126,500 (355)
ARTIFICIAL INTELLIGENCE FOR THE REAL WORLD
T. H. Davenport, Rajeev Ronanki
semanticscholar +1 more source
Reconstructing enzyme evolution by protein engineering
Natural enzyme evolution can be retraced by protein engineering methods such as directed evolution, rational design, and ancestral sequence reconstruction. These approaches reveal how enzymes emerged from ligand‐binding scaffolds, developed varying substrate preferences, formed oligomeric complexes, adapted to environmental changes, and evolved novel ...
Lukas Drexler +2 more
wiley +1 more source
Creating and using real-world evidence to answer questions about clinical effectiveness [PDF]
New forms of evidence are needed to complement evidence generated from randomised controlled trials (RCTs). Real-World Evidence (RWE) is a potential new form of evidence, but remains undefined.This paper sets to fill that gap by defining RWE as the ...
Crawford, Laura +5 more
core +1 more source
Background Heterogeneity in assessments of rheumatoid arthritis (RA) disease remission, based on physician judgment and patient self-reports versus standardized measures, have previously been reported.
Wenhui Wei +5 more
doaj +1 more source
The process of internalization of the Shiga toxin A subunit via formation of a complex with the Shiga toxin B subunit, which specifically binds to the Gb3 receptor. The peptide is designed to act as a carrier of drugs into cancer cells. Here, we explored the potential of peptides derived from the catalytic A subunit of Shiga toxin (STxA) to be drug ...
Giulia Opassi +6 more
wiley +1 more source
The little data book 2010 is a pocket edition of World Development Indicators (WDI) 2010. It is intended as a quick reference for users of the World Development Indicators database, book, and CD-ROM. The
World Bank
core +1 more source
Background Metabolic dysfunction-associated steatohepatitis (MASH) is commonly comorbid with metabolic syndrome; however, MASH can occur in the absence of metabolic syndrome.
Elliot B. Tapper +5 more
doaj +1 more source
Until 1994, rates of noncompliance for lipid-lowering therapies were largely drawn from clinical trials and showed favorable risks for drug discontinuation, ranging from 4-15% for 1-year risk to 11-30% for 5-year risk. Although cross-study comparisons are difficult to make because of variations in study design and measures collected, when evaluating ...
openaire +2 more sources
Investigating transcription factor dynamics in health and disease using FRAP
FRAP analysis of GFP‐tagged transcription factors reveals how molecular mobility and target engagement change in response to drug treatment. By combining live‐cell imaging, quantitative model fitting, and statistical analysis, this approach uncovers transcription factor dynamics linked to disease mechanisms, providing a powerful framework for ...
Kannan Govindaraj +3 more
wiley +1 more source
Conserved binding mode but diverse interfaces of MreC‐PBP2 interactions
The crystal structure of abMreC reveals a conserved two β‐barrel architecture and provides structural insights into its role within the bacterial elongasome. The abMreC–abPBP2 complex model identifies the molecular basis of MreC‐mediated PBP2 recognition, contributing to the regulation of peptidoglycan synthesis.
Hyunseok Jang +4 more
wiley +1 more source

